• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GlaxoSmithKline appoints Sir Philip Hampton to the board of directors

GlaxoSmithKline appoints Sir Philip Hampton to the board of directors

September 25, 2014
CenterWatch Staff

GlaxoSmithKline has announced that Sir Philip Hampton will join the board of the company as non-executive director January 2015 and will become deputy chairman effective April 2015. He will succeed Sir Christopher Gent.

The appointment follows an extensive succession planning process undertaken by the board over the last two years. The appointment of Hampton was recommended by the board’s Nominations Committee, chaired by Sir Deryck Maughan, GSK’s senior independent non-executive director.

Hampton has been chairman of The Royal Bank of Scotland Group (RBS) since February 2009. He previously was chairman of J Sainsbury and group finance director at Lloyds TSB Group, BT Group, BG Group, British Gas and British Steel, an executive director of Lazards and a non-executive director at RMC Group and Belgacom. He also is a former chairman of U.K. Financial Investments, which manages the U.K. Government’s shareholdings in banks.

Hampton is senior independent director of Anglo American, chairman of their Remuneration Committee and member of their Audit Committee.

He will leave RBS in 2015.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing